<DOC>
	<DOC>NCT01610284</DOC>
	<brief_summary>The purpose of this study is to determine wether the addition of daily BKM120 to fulvestrant is effective and safe in treating patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer refractory to aromatase inhibitor.</brief_summary>
	<brief_title>Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Locally advanced or metastatic breast cancer HER2negative and hormone receptorpositive status (common breast cancer classification tests) Postmenopausal woman A tumor sample must be shipped to a Novartis designated laboratory for identification of biomarkers (PI3K activation status) Progression or recurrence of breast cancer while on or after aromatase inhibitor treatment Measurable disease or non measurable disease bone lesions in the absence of measurable disease as per RECIST 1.1 Adequate bone marrow and organ function defined by laboratory values Previous treatment with PI3K inhibitors, AKT inhibitors, mTOR inhibitor or fulvestrant More than one prior chemotherapy line for metastatic disease Symptomatic brain metastases Increasing or chronic treatment (&gt; 5 days) with corticosteroids or another immunosuppressive agent Active heart (cardiac) disease as defined in the protocol Certain scores on an anxiety and depression mood questionnaires Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Hormone receptor positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>PI3K</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Refractory</keyword>
	<keyword>Aromatase inhibitor</keyword>
</DOC>